12 independently detected trends connected to this subject, with the latest coverage first.
This hub groups 12 separate news trends connected to Immunotherapy, spanning July 2, 2026 through September 1, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 81 article observations and 78 source signals, led by Health, Technology coverage. Use it to compare how individual events emerged, spread and changed over time.
New research suggests that the time of day cancer treatment is administered could significantly impact patient survival rates.
An experimental vaccine is generating immune responses against pancreatic cancer in high-risk individuals, according to early clinical findings.
Researchers have developed an oral nanomedicine that utilizes gut microbial metabolites to boost T cell effectiveness in cancer immunotherapy.
Research identifies high glucose levels as a factor in the thickening of cancer cells' sugar shields, potentially masking them from the immune system.
Engineered bispecific antibodies are targeting B-cell lymphoma by simultaneously engaging tumor cells and activating macrophages to destroy them.
Researchers are using CRISPR gene-editing technology to re-sensitize prostate tumors to immunotherapy treatments.
New research indicates that thymulin, a hormone from the thymus, may suppress age-related inflammation and improve cancer immunotherapy outcomes.
Scientists are investigating whether the affordable workout supplement creatine can assist in the fight against cancer.
A large-scale study has identified specific microbiomes residing within cancer tumors, signaling a shift in how oncology researchers view microbial interactions.
New clinical trial data suggests the tuberculosis BCG vaccine may reduce Alzheimer's risk by remodeling the brain's immune environment.
Scientists at USC have developed a technique to create an endless supply of cancer-fighting immune cells by enabling progenitor cells to self-renew.
New GPNMB CAR-T cell therapy shows potential to treat aggressive glioblastoma by targeting both tumors and their immune cell accomplices.